Identification of sitagliptin binding proteins by affinity purification mass spectrometry

Identification of sitagliptin binding proteins by affinity purification mass spectrometry

Type 2 diabetes mellitus (T2DM) is recognized as a serious public health concern with increasing incidence. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin has been used for the treatment of T2DM worldwide. Although sitagliptin has excellent therapeutic outcome, adverse effects are observed...

Full description

Bibliographic Details
Main Authors: Wang Xue-Ning, Sim Byu-Ri, Chen Hong, Zheng Yun-Xiao, Xue Jun-Biao, Wang Lei, Kong Wei-Sha, Zhou Kuan, Guo Shu-Juan, Hou Jing-Li, Zhang Jiong, Jiang He-Wei, Tao Sheng-Ce
Format: Article
Language:English
Published: China Science Publishing & Media Ltd. 2022-10-01
Series:Acta Biochimica et Biophysica Sinica
Subjects:
AP-MS
drug-target interaction
sitagliptin
SILAC
SPR
type 2 diabetes mellitus
Online Access:https://www.sciengine.com/doi/10.3724/abbs.2022142

Internet

https://www.sciengine.com/doi/10.3724/abbs.2022142

Similar Items